Monday, December 11, 2017 9:20:56 AM
ANTH - 1.60 Pre-market no at 1.83/1.84
Anthera Reports Positive Results From Phase 3 Study of Sollpura to Treat Exocrine Pancreatic Insufficiency
Anthera Reports Positive Results From Phase 3 Study of Sollpura to Treat Exocrine Pancreatic Insufficiency
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
